You are here: Welcome » pharmaceutical_companies » Emergent BioSolutions

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Both sides next revision
pharmaceutical_companies:emergent_biosolutions [2022/08/22 00:11]
pamela 		pharmaceutical_companies:emergent_biosolutions [2022/10/06 02:25] (current)
pamela [COVID-19]
Line 22: Line 22:
 In this second installment of the series “Engineering Contagion: Amerithrax, Coronavirus and the Rise of the Biotech-Industrial Complex,” Emergent Biosolution’s rise to prominence, made possible through acts of blatant corruption and the public-private revolving door, will be explored. The clear nexus between Big Pharma, Government and University-affiliated “Biosecurity Centers” offers a startling look into the Biotech-Industrial Complex that has long dominated U.S. biodefense policy and is now guiding much of the U.S. government’s response to the Coronavirus crisis. ((https://unlimitedhangout.com/2020/04/investigative-series/a-killer-enterprise-how-one-of-big-pharmas-most-corrupt-companies-plans-to-corner-the-covid-19-cure-market/)) In this second installment of the series “Engineering Contagion: Amerithrax, Coronavirus and the Rise of the Biotech-Industrial Complex,” Emergent Biosolution’s rise to prominence, made possible through acts of blatant corruption and the public-private revolving door, will be explored. The clear nexus between Big Pharma, Government and University-affiliated “Biosecurity Centers” offers a startling look into the Biotech-Industrial Complex that has long dominated U.S. biodefense policy and is now guiding much of the U.S. government’s response to the Coronavirus crisis. ((https://unlimitedhangout.com/2020/04/investigative-series/a-killer-enterprise-how-one-of-big-pharmas-most-corrupt-companies-plans-to-corner-the-covid-19-cure-market/))
  
 +==== Smallpox Vaccine Monopoly ====
  
 +Sanofi offloads smallpox vaccine business to Emergent BioSolutions in $125M deal
  
-===== COVID-19 =====+by Angus Liu | Jul 18, 2017 
 + 
 +Emergent BioSolutions is set to add the only FDA-approved smallpox vaccine to its portfolio through a $125 million deal with vaccine giant Sanofi Pasteur. 
 + 
 +The agreement means Emergent will inherit an existing CDC contract to build the national stockpile. That 10-year, $425 million contract has around $160 million left to be fulfilled before it ends in 2018. Emergent expects to negotiate a multiyear renewal as part of its involvement in the U.S. government’s counter-bioterrorism effort. 
 + 
 +Emergent CEO [[:Daniel Abdun-Nabi]] said in a statement that he expects the deal to contribute meaningful revenue growth to the company next year and help it reach a $1 billion revenue goal by 2020. But that depends on the FDA’s approval of a Canton, Massachusetts-based live viral manufacturing facility. ((https://web.archive.org/web/20170718181654/https://www.fiercepharma.com/vaccines/emergent-biosolutions-buys-sanofi-s-smallpox-vaccine-for-125m)) 
 + 
 + 
 +===== COVID-19 Vaccines =====
  
 In June 2020, [[AstraZeneca]] and Emergent partnered to manufacture their [[:COVID-19 vaccines|COVID-19 vaccine product]].((Blankenship, K. (2020, June 11). //AstraZeneca, Emergent BioSolutions sign $87M deal to produce U.S. supply of COVID-19 vaccine.// FiercePharma. https://archive.ph/I1uKJ)) ((Neri, M. B. (2020, June 11). //Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for AstraZeneca’s COVID-19 Vaccine Candidate.// Emergent BioSolutions. https://archive.ph/ivKBp)) In July 2020, Emergent was awarded a five-year contract with [[Johnson & Johnson]] to manufacture a core component of their [[:COVID-19 vaccines|COVID-19 vaccine product]].((Knapp, A. (2021, March 1). //Little-Known Publicly Traded Company Given Massive Deal To Manufacture One-Shot Covid-19 Vaccine.// Forbes. https://archive.ph/FCx7o)) In June 2020, [[AstraZeneca]] and Emergent partnered to manufacture their [[:COVID-19 vaccines|COVID-19 vaccine product]].((Blankenship, K. (2020, June 11). //AstraZeneca, Emergent BioSolutions sign $87M deal to produce U.S. supply of COVID-19 vaccine.// FiercePharma. https://archive.ph/I1uKJ)) ((Neri, M. B. (2020, June 11). //Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for AstraZeneca’s COVID-19 Vaccine Candidate.// Emergent BioSolutions. https://archive.ph/ivKBp)) In July 2020, Emergent was awarded a five-year contract with [[Johnson & Johnson]] to manufacture a core component of their [[:COVID-19 vaccines|COVID-19 vaccine product]].((Knapp, A. (2021, March 1). //Little-Known Publicly Traded Company Given Massive Deal To Manufacture One-Shot Covid-19 Vaccine.// Forbes. https://archive.ph/FCx7o))
 +
 +
 +==== Manufacturing Disaster ====
 +{{ :pharmaceutical_companies:emergent_vaccine_site_shut_down.png?400|}}
 +FDA orders shutdown at Emergent's troubled plant 2 weeks after handing J&J the keys
 +April 19, 2021 by Kevin Dunleavy 
 +
 +Johnson & Johnson’s takeover of COVID-19 vaccine manufacturing at an error-prone Emergent BioSolutions plant in Baltimore didn’t last long.
 +
 +Two weeks after the U.S. stepped in and handed control of vaccine manufacturing at the plant to J&J, Emergent agreed to stop producing drug substance there. 
 +
 +In March, the factory had to discard up to 15 million vaccine doses when it mixed up materials for the J&J and AstraZeneca vaccines. The New York Times reported  an additional batch of between 10 million and 15 million doses of the AZ vaccine was lost last November because of suspected contamination at the plant.  ((https://web.archive.org/web/20210419145104/https://www.fiercepharma.com/pharma/at-request-fda-emergent-s-troubled-baltimore-plant-suspends-j-j-vaccine-production))
Back to top